Obesity is a big problem in today's time due to modern lifestyles and poor diets. Children, old people, and elderly people of all ages are struggling with obesity. Wherever you look, whether it is social media, YouTube, TV, or newspaper, you are full of different types of tips to lose weight or videos are going viral. There is a lot on social media regarding gym, exercise, yoga, diet, and fitness goals. Now in the midst of all this, if your eyes fall on the news that 'just one injection in a week will reduce the weight by 15 kg', then what will be your reaction? Yes, it is hard to believe, but it is true that recently, pharmaceutical giant Eli Lilly has mentioned a drug to reduce weight if it comes into the market. Then there will be panic in the world.
Actually, Eli Lilly said, 'We have recently done a clinical trial of weight loss medicine, the results of which have been very good. The name of this medicine is Tirzepatide. The most important thing about Tirzepatide medicine is that this medicine is used for the treatment of type 2 diabetes under the name 'Monjaro brand'. Actually, type-2 diabetes patients take this medicine once a week in the form of an injection. Now Eli Lilly is demanding that this drug should be launched in the US market in the field of weight loss. So that people can get rid of diseases like obesity. Because nowadays obesity is the root of all diseases. Eli Lilly said that this medicine for type 2 diabetes was used on obese people for 72 weeks and the result is quite satisfactory.
Results of the medical trial of Tirzepatide drug
According to Eli Lilly, during this entire medical trial, people who were given an overdose of Tirzepatide drug. His weight was reduced by more than 15 kg in a week. Mild side effects of this medicine were also seen on the patient, such as gastrointestinal, nausea, vomiting, and upset stomach, but the results were quite good. The Indiana-based company said it plans to complete its submission to US authorities in the coming weeks and the drug could be on the market by the end of 2023.
In a scientific trial published in the year 2021, it was kept that the people who were included in this research. He did not have diabetes. Only overweight people were included in this. About 21 per cent of the people involved in this research lost weight.
This claim is being made regarding the drug Tirzepatide
Like other medicines, terzepetide has also become very famous for reducing weight. For your information, let us tell you that terzepetide mimics the gastrointestinal hormone GLP-1. After consuming this medicine, your brain activates the receptors of loss of appetite. However, from May 2022, Monjaro is used in the US for the treatment of diabetes patients. Some doctors already recommend this medicine to people to lose weight. Many experts see GLP-1 analogues as a game-changer, as they cause much greater weight loss than drugs available on the market. It has also been revealed in research that 40 per cent of Americans are suffering from diseases like obesity, this medicine will create panic in the world of medicine. It is being speculated. According to Morgan Stanley, the global market for obesity treatment could be worth $54 billion by 2030.
